Royalty Pharma to Showcase Achievements and Share Business Update at J.P. Morgan Healthcare Conference Royalty Pharma plc today provided an update on its business performance, including recent key accomplishments. Pablo Legorreta, Royalty Pharma’s Chief Executive Officer and Chairman of the…
BCG and Hippocratic AI Announce Strategic Collaboration to Deploy Agentic AI Across Biopharma and Medtech Boston Consulting Group (BCG) and Hippocratic AI today announced a global collaboration aimed at transforming the biopharma and medtech industries through the responsible implementation of…
At JPM26, Policy and Politics Will Loom Large for Pharma as Biotech Sees the Sun Heading into the J.P. Morgan Healthcare Conference for the past few years, industry watchers have tried to will deals into existence with effusive optimism despite…
Highlights recent progress across key R&D programs and outlines strategic priorities for 2026 Enanta Pharmaceuticals, Inc. a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced updates on its research and development programs…
The appointment strengthens leadership of the company’s U.S. BioPharmaceuticals operations and strategic growth AstraZeneca has named Rick R. Suarez Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit.Suarez will lead the execution of the Company’s previously…
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance BOSTON a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced financial guidance for full year 2026. Throughout…
Alnylam Pharmaceuticals Announces Strategic Refresh of Board of Directors to Propel Next Phase of Growth Alnylam Pharmaceuticals, Inc.the global pioneer and leader in RNA interference (RNAi) therapeutics, today announced a significant strategic evolution of its Board of Directors, reflecting the…
Mirum Pharmaceuticals Enrolls First Participant in BLOOM Phase 2 Study Evaluating MRM-3379 for Fragile X Syndrome Mirum Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and delivering innovative therapies for rare diseases, announced today a key milestone in its development…
Circle Pharma Appoints Anne E. Borgman, M.D., as Chief Medical Officer, Strengthening Leadership Team to Advance Next-Generation Macrocycle Oncology Pipeline Circle Pharma, Inc., a clinical-stage biopharmaceutical company advancing a new class of targeted macrocycle therapeutics designed to address some of…
Arrowhead Pharmaceuticals Reports Fiscal Year 2025 Financial Results and Highlights Major Regulatory and Clinical Milestones Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its financial results for the fiscal year ending September 30, 2025, alongside a comprehensive review of recent scientific,…
Hercules Pharmaceuticals Announces Membership in the Healthcare Distribution Alliance and Board Appointment of Timothy Ward Hercules Pharmaceuticals (Hercules), a national leader in pharmaceutical distribution and a rapidly growing provider-aligned group purchasing organization (GPO), announced today that it has officially joined…
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran), Marking a Major Advancement in Treatment for Familial Chylomicronemia Syndrome Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced a landmark achievement today with the U.S. Food and Drug Administration’s (FDA) approval of REDEMPLO® (plozasiran).…
